- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research | 267 | ACCESS Newswire | October 22 investor event will explore eXoZymes' commercialization, manufacturing economics, path to market launch, growth strategy, and milestones ahead. LOS ANGELES, CA / ACCESS Newswire / October... ► Artikel lesen | |
| 09.10. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.09. | Exozymes gibt Termin für Hauptversammlung 2026 und Stichtag bekannt | 2 | Investing.com Deutsch | ||
| 18.09. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | exozymes partners with Curia for NCT manufacturing scale-up | 2 | Investing.com | ||
| 08.09. | eXoZymes und Curia kooperieren bei der Skalierung der NCT-Produktion | 2 | Investing.com Deutsch | ||
| EXOZYMES Aktie jetzt für 0€ handeln | |||||
| 08.09. | eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT | 475 | ACCESS Newswire | Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027 LOS ANGELES, CA / ACCESS Newswire / September 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes")... ► Artikel lesen | |
| 20.08. | eXoZymes reports Q2 results | 1 | Seeking Alpha | ||
| 20.08. | eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today | 624 | ACCESS Newswire | Management to host Q2 2026 update at 5PM ET / 2PM PT, today. LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes... ► Artikel lesen | |
| 18.08. | exoZymes reports 10-fold productivity gain in NCT manufacturing | 1 | Investing.com | ||
| 18.08. | eXoZymes meldet zehnfache Produktivitätssteigerung bei der NCT-Herstellung | 1 | Investing.com Deutsch | ||
| 18.08. | eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets | 476 | ACCESS Newswire | Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing.Estimated manufacturing cost equivalent has... ► Artikel lesen | |
| 13.08. | EXOZYMES INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026 | 549 | ACCESS Newswire | Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar... ► Artikel lesen | |
| 23.07. | eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing | 564 | ACCESS Newswire | Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes.The 9-month project awarded... ► Artikel lesen | |
| 26.06. | eXoZymes erhält 2 Millionen US-Dollar vom NIH zur Weiterentwicklung von Cannabinoid-Analoga für die Arzneimittelforschung | 1 | Bionity.com | ||
| 26.06. | EXOZYMES INC. - 8-K, Current Report | - | SEC Filings | ||
| 24.06. | Cannabinoid-Forschung: eXoZymes sichert sich NIH-Zuschuss über 2 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 24.06. | exoZymes receives $2M NIH grant for cannabinoid research | 1 | Investing.com | ||
| 24.06. | eXoZymes awarded $2M NIH Grant to advance cannabinoid analogs for drug discovery | 2 | Seeking Alpha |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 9,810 | -3,63 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,739 | -18,26 % | Inovio wins case in dispute with VGXI, GeneOne Life Science | ||
| INFLARX | 1,368 | -0,58 % | InflaRx bekommt nur eine 4+: Warum unsere Experten so kritisch sind - Dringend vor Börsenschluss handeln! | ||
| INTELLIA THERAPEUTICS | 10,400 | -1,33 % | Intellia Therapeutics-Aktie: Sind 80 US$ möglich? | Die Intellia-Therapeutics-Aktie notiert aktuell bei 12,37 US$ und damit mehr als -90% unter ihrem bisherigen Rekordhoch. Nach dem Ausbruch aus dem langjährigen Abwärtstrend versucht der Biotech-Titel... ► Artikel lesen | |
| EDITAS MEDICINE | 2,240 | -2,18 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,350 | -2,51 % | 6,4 Millionen US-Dollar pro Patient: Warum Medtronic, Lifeward und NurExone an drei Stufen der Rückenmarksversorgung ansetzen | ||
| IBIO | 0,793 | +7,31 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,010 | -7,30 % | Geron Corporation: Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026 | ||
| IMMUNITYBIO | 7,720 | -1,15 % | ImmunityBio completes database lock for bladder cancer trial | ||
| IMMATICS | 6,755 | +1,05 % | Stifel stuft Immatics mit "Buy" ein - Großes Potenzial in der Melanom-Pipeline | ||
| MYRIAD GENETICS | 4,922 | +0,72 % | TD Cowen belässt Myriad Genetics nach Verkauf an Labcorp auf "Hold" | ||
| MANNKIND | 2,712 | -0,95 % | MannKind auf der 10. Jährlich stattfindenden Chardan Healthcare Conference: Pipeline erweitert sich | ||
| GINKGO BIOWORKS | 8,902 | +1,32 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| IMMUNIC | 6,710 | +2,13 % | EQS-News: Immunic AG: Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting | Issuer: Immunic AG
/ Key word(s): Conference/Study results
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 13,180 | -0,45 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
Das Unternehmen EXOZYMES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,920 Euro und damit -5,77 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXOZYMES INC finden Sie auf Wallstreet Online.